Torrent Pharmaceuticals is currently trading at Rs. 3967.70, up by 40.75 points or 1.04% from its previous closing of Rs. 3926.95 on the BSE.
The scrip opened at Rs. 3933.45 and has touched a high and low of Rs. 3977.00 and Rs. 3913.30 respectively. So far 690 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4124.95 on 20-Jan-2026 and a 52 week low of Rs. 2891.45 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 4124.95 and Rs. 3910.65 respectively. The current market cap of the company is Rs. 132619.85 crore.
The promoters holding in the company stood at 68.31%, while Institutions and Non-Institutions held 25.27% and 6.42% respectively.
Torrent Pharmaceuticals has acquired 37,82,566 equity shares of J.B. Chemicals & Pharmaceuticals (JB Chemicals), representing 2.36% of the equity share capital of JB Chemicals on a fully diluted basis, from certain employees of JB Chemicals in accordance with the share purchase agreement dated July 3, 2025 executed between the company and certain employees of JB Chemicals.
Following the aforesaid acquisition, the company holds an aggregate of 7,82,65,402 equity shares of JB Chemicals, representing 48.75% of the equity share capital of JB Chemicals on a fully diluted basis.
Torrent Pharmaceuticals (Torrent Pharma) is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: